Bone Marrow Lymphoma

  • Megan ParillaEmail author
  • Girish Venkataraman
Part of the Atlas of Anatomic Pathology book series (AAP)


Lymphomas are malignant hematopoietic neoplasms arising from mature lymphoid cells that typically reside within extramedullary lymphoid tissues, including the lymph nodes and spleen. However, lymphomas can frequently involve the extranodal tissues, including peripheral blood (leukemia) and/or the bone marrow. There are even rare instances in which the bone marrow is the sole location of involvement by lymphoma [1]. A variety of infiltration patterns may be observed (paratrabecular, interstitial, or sinusoidal) in the various B and T cell lymphomas, besides varying background microenvironment inflammatory cells (e.g., in Hodgkin lymphoma, T cell lymphomas). Both pattern and microenvironment are useful features that assist in characterizing marrow involvement by providing clues to the nature of the lymphoma in cases where marrow involvement is the presenting feature. Ancillary studies such as flow cytometry and immunohistochemistry are both complementary studies in evaluating for marrow involvement.


Marrow involvement Non-Hodgkin lymphoma Bone marrow infiltration Classical Hodgkin lymphoma T cell lymphoma 


  1. 1.
    Chang H, Hung YS, Lin TL, Wang PN, Kuo MC, Tang TC, et al. Primary bone marrow diffuse large B cell lymphoma: a case series and review. Ann Hematol. 2011;90(7):791–6.CrossRefPubMedGoogle Scholar
  2. 2.
    Zwarthoed C, El-Galaly TC, Canepari M, Ouvrier MJ, Viotti J, Ettaiche M, et al Prognostic value of bone marrow tracer uptake pattern in baseline PET scan in Hodgkin Lymphoma: results from an International Collaborative Study. J Nucl Med. 2017. pii: jnumed.116.184218. doi:
  3. 3.
    Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059–68.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–90.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Wiestner A, Rosenwald A, Barry TS, Wright G, Davis RE, Henrickson SE, et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood. 2003;101(12):4944–51.CrossRefPubMedGoogle Scholar
  6. 6.
    Schade U, Bock O, Vornhusen S, Jäger A, Büsche G, Lehmann U, et al. Bone marrow infiltration pattern in B-cell chronic lymphocytic leukemia is related to immunoglobulin heavy-chain variable region mutation status and expression of 70-kd zeta-associated protein (ZAP-70). Hum Pathol. 2006;37(9):1153–61.CrossRefPubMedGoogle Scholar
  7. 7.
    Swords R, Bruzzi J, Giles F. Recent advances in the diagnosis and therapy of Richter’s syndrome. Med Oncol. 2007;24(1):17–32.CrossRefPubMedGoogle Scholar
  8. 8.
    Del Giudice I, Davis Z, Matutes E, Osuji N, Parry-Jones N, Morilla A, et al. IgVH genes mutation and usage, ZAP-70 and CD38 expression provide new insights on B-cell prolymphocytic leukemia (B-PLL). Leukemia. 2006;20(7):1231–7.CrossRefPubMedGoogle Scholar
  9. 9.
    Del Giudice I, Osuji N, Dexter T, Brito-Babapulle V, Parry-Jones N, Chiaretti S, et al. B-cell prolymphocytic leukemia and chronic lymphocytic leukemia have distinctive gene expression signatures. Leukemia. 2009;23(11):2160–7.CrossRefPubMedGoogle Scholar
  10. 10.
    Randen U, Trøen G, Tierens A, Steen C, Warsame A, Beiske K, et al. Primary cold agglutinin-associated lymphoproliferative disease: a B-cell lymphoma of the bone marrow distinct from lymphoplasmacytic lymphoma. Haematologica. 2014;99(3):497–504.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Johrens K, Stein H, Anagnostopoulos I. T-bet transcription factor detection facilitates the diagnosis of minimal hairy cell leukemia infiltrates in bone marrow trephines. Am J Surg Pathol. 2007;31(8):1181–5.CrossRefPubMedGoogle Scholar
  12. 12.
    Venkataraman G, Aguhar C, Kreitman RJ, Yuan CM, Stetler-Stevenson M. Characteristic CD103 and CD123 expression pattern defines hairy cell leukemia: usefulness of CD123 and CD103 in the diagnosis of mature B-cell lymphoproliferative disorders. Am J Clin Pathol. 2011;136(4):625–30.CrossRefPubMedGoogle Scholar
  13. 13.
    Tiacci E, Trifonov V, Schiavoni G, Holmes A, Kern W, Martelli MP, et al. BRAF mutations in hairy-cell leukemia. N Engl J Med. 2011;364(24):2305–15.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Karube K, Guo Y, Suzumiya J, Sugita Y, Nomura Y, Yamamoto K, et al. CD10-MUM1+ follicular lymphoma lacks BCL2 gene translocation and shows characteristic biologic and clinical features. Blood. 2007;109(7):3076–9.PubMedGoogle Scholar
  15. 15.
    Treon SP, Xu L, Yang G, Zhou Y, Liu X, Cao Y, et al. MYD88 L265P somatic mutation in Waldenstrom’s macroglobulinemia. N Engl J Med. 2012;367(9):826–33.CrossRefPubMedGoogle Scholar
  16. 16.
    Cohen PL, Kurtin PJ, Donovan KA, Hanson CA. Bone marrow and peripheral blood involvement in mantle cell lymphoma. Br J Haematol. 1998;101(2):302–10.CrossRefPubMedGoogle Scholar
  17. 17.
    Salaverria I, Royo C, Carvajal-Cuenca A, Clot G, Navarro A, Valera A, et al. CCND2 rearrangements are the most frequent genetic events in cyclin D1(-) mantle cell lymphoma. Blood. 2013;121(8):1394–402.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Wlodarska I, Dierickx D, Vanhentenrijk V, Van Roosbroeck K, Pospísilová H, Minnei F, et al. Translocations targeting CCND2, CCND3, and MYCN do occur in t(11;14)-negative mantle cell lymphomas. Blood. 2008;111(12):5683–90.CrossRefPubMedGoogle Scholar
  19. 19.
    Sehn LH, Scott DW, Chhanabhai M, Berry B, Ruskova A, Berkahn L, et al. Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol. 2011;29(11):1452–7.CrossRefPubMedGoogle Scholar
  20. 20.
    Rajala HL, Porkka K, Maciejewski JP, Loughran TP Jr, Mustjoki S. Uncovering the pathogenesis of large granular lymphocytic leukemia-novel STAT3 and STAT5b mutations. Ann Med. 2014;46(3):114–22.CrossRefPubMedGoogle Scholar
  21. 21.
    Herling M, Patel KA, Teitell MA, Konopleva M, Ravandi F, Kobayashi R, et al. High TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemia. Blood. 2008;111(1):328–37.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Higgins JP, van de Rijn M, Jones CD, Zehnder JL, Warnke RA. Peripheral T-cell lymphoma complicated by a proliferation of large B cells. Am J Clin Pathol. 2000;114(2):236–47.CrossRefPubMedGoogle Scholar
  23. 23.
    Macon WR, Levy NB, Kurtin PJ, Salhany KE, Elkhalifa MY, Casey TT, et al. Hepatosplenic alphabeta T-cell lymphomas: a report of 14 cases and comparison with hepatosplenic gammadelta T-cell lymphomas. Am J Surg Pathol. 2001;25(3):285–96.CrossRefPubMedGoogle Scholar
  24. 24.
    Ponzoni M, Ferreri AJ, Campo E, Facchetti F, Mazzucchelli L, Yoshino T, et al. Definition, diagnosis, and management of intravascular large B-cell lymphoma: proposals and perspectives from an international consensus meeting. J Clin Oncol. 2007;25(21):3168–73.CrossRefPubMedGoogle Scholar
  25. 25.
    Roemer MG, Advani RH, Ligon AH, Natkunam Y, Redd RA, Homer H, et al. PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome. J Clin Oncol. 2016;34(23):2690–7.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med. 2015;372(4):311–9.CrossRefPubMedGoogle Scholar
  27. 27.
    Dogan A, Burke JS, Goteri G, Stitson RN, Wotherspoon AC, Isaacson PG. Micronodular T-cell/histiocyte-rich large B-cell lymphoma of the spleen: histology, immunophenotype, and differential diagnosis. Am J Surg Pathol. 2003;27(7):903–11.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2018

Authors and Affiliations

  1. 1.Department of PathologyUniversity of Chicago Medical CenterChicagoUSA

Personalised recommendations